5-(naphthalen-1-yl)imidazo[1,5-a]pyridine hydrochloride | 697746-17-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-(naphthalen-1-yl)imidazo[1,5-a]pyridine hydrochloride
• 英文别名: 5-Naphthalen-1-ylimidazo[1,5-a]pyridine;hydrochloride
• CAS: 697746-17-1
• 化学式: C₁₇H₁₂N₂*ClH
• 分子量: 280.757
• InChiKey: OVBYYFFTIMPHGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.58
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.3
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  5-naphthalen-1-yl-imidazo[1,5-a]pyridine 在 盐酸 作用下， 以 1,4-二氧六环 、 水 、 丙酮 为溶剂， 反应 1.0h， 以100%的产率得到5-(naphthalen-1-yl)imidazo[1,5-a]pyridine hydrochloride
  参考文献：
  名称：

  硫醚辅助铜催化咪唑并[1,5-a]吡啶的C5-H芳基化

  摘要：

  在 C3 位的乙硫基团的帮助下，实现了Cu 催化的咪唑并[1,5- a ]吡啶与芳基碘化物的区域选择性 C5-H 芳基化。该导向基团可以很容易地去除以提供一系列 5-(杂)芳基咪唑并[1,5- a ]吡啶衍生物。该反应具有多种功能，并且与空间位阻底物相容。

  DOI：

  10.1021/acs.orglett.2c01404

文献信息

• [EN] IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES<br/>[FR] DERIVES D'IMIDAZO[1,5A]PYRIDINE ET METHODES DE TRAITEMENT DES MALADIES MEDIEES PAR L'ALDOSTERONE
  申请人：NOVARTIS AG

  公开号：WO2004046145A1

  公开（公告）日：2004-06-03

  Compounds of the formula (I) provide pharmacological agents which are inhibitors of the P450 enzyme, aldosterone synthase, and thus may be employed for the treatment of aldosterone mediated conditions. Accordingly, the compounds of formula (I) may be employed for prevention, delay of progression, or treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post­myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction. Preferred are the compounds of formula (I) which are selective inhibitors of aldosterone synthase devoid of undesirable side effects due to general inhibition of cytochrome P450 enzymes.

  公式（I）的化合物提供了药理学制剂，它们是P450酶、醛固酮合成酶的抑制剂，因此可用于治疗醛固酮介导的疾病。因此，公式（I）的化合物可用于预防、延缓进展或治疗低钾血症、高血压、充血性心力衰竭、肾衰竭，特别是慢性肾衰竭、再狭窄、动脉粥样硬化、X综合征、肥胖症、肾病、心肌梗死后、冠心病、胶原蛋白增生、高血压和内皮功能障碍后的纤维化和重塑。优选的是公式（I）的化合物，它们是醛固酮合成酶的选择性抑制剂，不会因为对细胞色素P450酶的一般抑制而产生不良副作用。
• Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases
  申请人：Firoodznia Fariborz

  公开号：US20060058342A1

  公开（公告）日：2006-03-16

  Compounds of the formula (I) provide pharmacological agents which are inhibitors of the P450 enzyme, aldosterone synthase, and thus may be employed for the treatment of aldosterone mediated conditions. Accordingly, the compounds of formula (I) may be employed for prevention, delay of progression, or treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction. Preferred are the compounds of formula (I) which are selective inhibitors of aldosterone synthase devoid of undesirable side effects due to general inhibition of cytochrome P450 enzymes.

  公式（I）的化合物提供了药理学制剂，可作为P450酶和醛固酮合成酶的抑制剂，因此可用于治疗醛固酮介导的疾病。因此，公式（I）的化合物可用于预防、延缓进展或治疗低钾血症、高血压、充血性心力衰竭、肾衰竭，特别是慢性肾衰竭、再狭窄、动脉粥样硬化、X综合症、肥胖症、肾病、心肌梗死后、冠心病、胶原形成增加、高血压和内皮功能障碍后的纤维化和重塑。首选的是公式（I）的化合物，其选择性地抑制醛固酮合成酶，不具有由于细胞色素P450酶的一般抑制而产生的不良副作用。
• IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES
  申请人：Firooznia Fariborz

  公开号：US20070197582A1

  公开（公告）日：2007-08-23

  Compounds of the formula (I) provide pharmacological agents which are inhibitors of the P450 enzyme, aldosterone synthase, and thus may be employed for the treatment of aldosterone mediated conditions. Accordingly, the compounds of formula (I) may be employed for prevention, delay of progression, or treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction. Preferred are the compounds of formula (I) which are selective inhibitors of aldosterone synthase devoid of undesirable side effects due to general inhibition of cytochrome P450 enzymes.

  公式（I）的化合物可提供药理作用剂，其为P450酶、醛固酮合成酶的抑制剂，因此可用于治疗醛固酮介导的疾病。因此，公式（I）的化合物可用于预防、延缓进展或治疗低钾血症、高血压、充血性心力衰竭、肾衰竭、特别是慢性肾衰竭、再狭窄、动脉粥样硬化、X综合症、肥胖症、肾病、心肌梗死后、冠心病、胶原形成增加、高血压和内皮功能障碍后的纤维化和重塑。优选的是公式（I）的化合物，其为醛固酮合成酶的选择性抑制剂，不会因对细胞色素P450酶的一般抑制而产生不良副作用。
• IMIDAZO[1,5A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES
  申请人：Novartis AG

  公开号：EP1565463B1

  公开（公告）日：2008-06-11
• IMIDAZO[1,5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES
  申请人：Novartis AG

  公开号：EP1565463A1

  公开（公告）日：2005-08-24